Idogen AB
Year-end report

January–December 2018

Idogen AB Year-end report

1 January–31 December 2018

FOURTH QUARTER (OCTOBER–DECEMBER 2018)

- Other operating income amounted to KSEK 3,766 (0)
- Operating loss amounted to KSEK -4,796 (-7,289)
- Loss for the period amounted to KSEK -4,806 (-7,315)
- Cash flow from operating activities was KSEK -432 (-8,250)
- Loss per share before dilution was SEK -0.19 (-0.35). Loss per share after dilution was SEK -0.19 (-0.35)

PERIOD (JANUARY–DECEMBER 2018)

- Other operating income amounted to KSEK 3,766 (0)
- Operating loss amounted to KSEK -27,861 (-21,299)
- Loss for the period amounted to KSEK -27,634 (-21,322)
- Cash flow from operating activities was KSEK -10,394 (-19,906)
- Loss per share before dilution was SEK -1.27 (-1.32). Loss per share after dilution was SEK -1.27 (-1.32)
- The proposed dividend is SEK 0.00/share (0.00)

SIGNIFICANT EVENTS IN THE FOURTH QUARTER

- In October, Canada's patent office announced that it intended to approve Idogen's patent application related to the second patent family, which pertains to induction of IDO in autoimmune diseases and transplantation.
- In October, the company announced its decision to hold a rights issues with a "top" guarantor.
- In November, an Extraordinary General Meeting was held where a decision was taken approving the Board's recommendation for a rights issue of shares.
- In November, Idogen demonstrated proof-of-principle in a model of autoimmune disease, autoimmune uveitis. The model in the study is T-cell driven and the effects are expected to therefore be relevant for the treatment of other autoimmune diseases.
- In December, Idogen published the outcome of the company's rights issue that was subscribed to 80% and raised capital of approximately MSEK 38.7 for Idogen after issue costs, which is sufficient to support operations until the third quarter of 2020.

SIGNIFICANT EVENTS DURING THE PERIOD

- In January, the EU paid the first subpayment of the Horizon 2020 grant, an amount of MEUR 1.2. In December, a further MEUR 0.3 was paid. The remaining MEUR 1.4 will be paid out over the next 24 months.
- In April, Idogen announced that the company had postponed the planned start of the Phase I/IIa clinical trial of the IDO 8 project until early 2020 and initiated an expanded optimisation process. Accordingly, the planned start of the first clinical trial in the IDO T project was also postponed until the end of 2020 at the earliest.
- Idogen strengthened its research organisation in the second quarter with the appointment of Hanne Risager Romedahl as new Chief Scientific Officer. Hanne took up her position on 7 May and replaces Anette Sundstedt who has remained with the company in the role of scientific expert.
- In August, the Board decided to add a third therapeutic area to Idogen's project portfolio – autoimmune diseases, IDO AID.
- In September, Idogen's IDO 8 was granted orphan drug designation in the US.
- Work transferring the Idogen share from Spotlight to Nasdaq First North began.

SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD

- The company announced in January that it extends and broadens the preclinical development program for the tolerogenic cell therapy, which may delay the clinical studies for IDO 8 and IDO T by six months, starting H2 2020 for IDO 8 and H1 2021 for IDO T.
- Arctic Securities was chosen as Corporate Advisor (CA) ahead of the listing on First North
- No other significant events occurred after the end of the period that affected the results or financial position.



CONDENSED EARNINGS AND CASH FLOW

(Amounts in KSEK unless otherwise stated)	2018 3 months Oct-Dec	2017 3 months Oct-Dec	2018 12 months Jan-Dec	2017 12 months Jan-Dec
Other operating income	3,766	0	3,766	0
Operating expenses	-8,562	-7,289	-31,627	-21,299
Operating loss	-4,796	-7,289	-27,861	-21,299
Loss for the period after net financial items	-4,806	-7,315	-27,634	-21,322
Average number of shares	24,998,490	20,778,472	21,843,166	16,207,516
Average number of warrants	8,555,883	17,111,766	11,790,710	7,969,864
Loss per share before dilution (SEK)	-0.19	-0.35	-1.27	-1.32
Loss per share after dilution (SEK)	-0.19	-0.35	-1.27	-1.32
Cash flow from operating activities	-432	-8,250	-10,394	-19,906
KEY FIGURES				
Working capital	42,306	33,894	42,306	33,894
Acid-test ratio (%)	305	895	305	895
Equity/assets ratio (%)	71	90	71	90
Loss per share before dilution	-0.19	-0.35	-1.27	-1.32
Average number of shares	24,998,490	20,778,472	21,843,166	16,207,516

Definitions of Key Figures

Working capital
Total current assets (including cash and cash equivalents) less current liabilities.

Acid-test ratio
Total current assets (including cash and cash equivalents) relative to current liabilities.

Equity/assets ratio
Shareholders' equity in relation to balance sheet total

Earnings per share before dilution
Profit after tax divided by the average number of shares for the period.

Average number of shares
The average number of shares on the day when the new issue is registered.

CEO comment

During the fourth quarter of 2018, Idogen announced promising results from a preclinical trial in the new development field of autoimmune diseases, obtained stronger IP rights for our tolerogenic cell therapy and conducted a rights issue that secures company operations until the third quarter of 2020. In addition, we have made a great deal of progress preparing for the transfer from the Spotlight Stock Market to Nasdaq First North.

The rights issue was concluded, generating proceeds of MSEK 38.7 after issue costs, and gave us new strategic shareholders with a clear long-term commitment. The IDO 8 project is being developed for the treatment of severe haemophilia. Some patients with haemophilia A develop inhibitory antibodies against their critical treatment with coagulation factor VIII. Treatment with IDO 8 is based on the reprogramming of cells from the patient's own blood to counteract the formation of inhibitory antibodies.

Autoimmune disease is the most recent of the three therapeutic areas on which Idogen is building its business – together with haemophilia and kidney transplantation. All projects are based on Idogen's knowledge of how to create tolerogenic dendritic cells. Only three months after the announcement that the project portfolio was to be extended with a project in autoimmune diseases, Idogen could in November announce the successful outcome of a preclinical trial in a model of autoimmune uveitis – an autoimmune eye disease that in its most serious form can result in blindness. The model in the study is T-cell driven and the effects are expected to therefore be relevant for the treatment of other autoimmune diseases.

The results of the study provide important documentation for the risk/benefit analysis that will be conducted as soon as we have completed additional preclinical trials for other autoimmune diseases and with other methods of administration. On the basis of this analysis, we will decide which autoimmune disease to prioritise in project development moving forward.

Canada's patent office announced during the autumn its intention to approve our patent for induction of the IDO enzyme for the treatment of autoimmune diseases and transplant rejection. The patent is valid until December 2031 with a potential option for an extension assuming an application for supplementary protection is submitted and approved.

After the end of the reporting period, we decided to extend and broaden the preclinical development program for our tolerogenic cell therapies. The decision follows results obtained from an improved assessment model and we need to analyse the effects of other potential treatment methods that are not based on zebularine – the substance that until now has formed a component of the method we have focused on to date. The newly developed assessment method offers us the potential to document in greater detail the effects of various methods to influence immune cells before taking a final decision on which is the most appropriate. This allows us to create sounder documentation prior to the start of future clinical trials, and the extension of the preclinical development program could delay the start of clinical trials of IDO 8 and IDO T by six months. Clinical trials of IDO 8 are therefore expected to start in the second half of 2020 and of IDO T during the first half of 2021.

We see strong potential to use the improved assessment method to further create a robust technology in order to provide tolerogenic cell therapies in the future that can facilitate the lives of severely exposed patient groups.

Lars Hedbys

Chief Executive Officer

Idogen in brief

Idogen (Spotlight Stock Market: IDOGEN) is a Swedish biotechnology company based in Lund. Idogen develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The term "tolerogenic" refers to the immune system's selective tolerance of a specific pathogenic or immune activating antigen following treatment with Idogen's therapy. Idogen's intention is to revolutionise the treatment of several disorders in which the body's immune system does not function as it should, and for which there is a major unmet medical need – such as in autoimmune diseases, organ transplant rejection and in patients who have developed anti-drug antibodies.

IDOGEN'S PRODUCT PORTFOLIO

Idogen's most advanced product candidate, IDO 8, is designed for patients with severe haemophilia A, who have developed inhibitory antibodies against their critical treatment with coagulation factor VIII (FVIII). The company also develops IDO T – a tolerogenic cell therapy to prevent organ transplant rejection, primarily kidney transplant rejection. IDO T is expected to reduce the need for immunosuppressive drugs and improve transplant survival, thereby reducing the risk of cancer and infections. Idogen recently added a third therapeutic area in autoimmune diseases, IDO AID, to its project portfolio. Idogen's research unit is currently evaluating the potential of the company's technology in a group of autoimmune diseases all with major unmet medical need, and where a treatment could be granted orphan drug designation.

IDOGEN'S TECHOLOGY

The ability to create a properly functioning immune system that protects and defends the body from invasion by foreign organisms – such as viruses, bacteria and tumours – would revolutionise the treatment of patients with severe chronic illness. Idogen aims to be part of this revolution. The company contributes by developing cell therapies, which is a different approach to conventional medical therapies. Instead of administering a chemical substance to the body, the patient is treated with their own cells. Idogen's treatment is based on dendritic cells, types of white blood cells, that play a central role in the immune system, because they control other immune system cells' recognition of what belongs in the body (self) and what is foreign (non-self).

FUTURE AND STRATEGY

Idogen's intention is to enter into collaboration and/or license agreements based on the clinical trial results in each project. Several large pharmaceutical companies have already shown a major interest. In recent years, a number of smaller cell therapy companies have signed collaboration and license agreements with global pharmaceutical companies, with attractive terms.

Idogen´s vision is the first tolerogenic cell therapy with long-term effect for the treatment of patients with large unmet medical needs

Financial information

FINANCIAL PERFORMANCE FOR THE FOURTH QUARTER, 1 OCTOBER–31 DECEMBER 2018

Other operating income

Other operating income for the quarter amounted to KSEK 3,766 (0) and refers to the Horizon 2020 grant.

Operating profit/loss

Operating loss for the quarter amounted to KSEK -4,796 (-7,289), a change of KSEK +2,493 compared with the year-on-year quarter. Adjustments for EU grants yielded a positive contribution while an increase in resources for development resulted in higher costs.

Profit/loss for the period

Loss for the period amounted to KSEK -4,806 (-7,315). Loss per share before dilution amounted to SEK -0.19 (-0.35) and loss per share after dilution to SEK -0.19 (-0.35).

Liquidity and cash flow

- Cash flow from operating activities was KSEK -432 (-8,250)
- Cash flow from investing activities was KSEK -466 (-2,703). During the quarter, investments were made in laboratory equipment and patents.
- Cash flow from financing activities was KSEK +38,749 (0).
- Cash flow for the quarter was KSEK +37,851 (-10,953).
- At the end of the period, the Group's cash and cash equivalents amounted to KSEK 61,605 (36,943).

FINANCIAL PERFORMANCE FOR THE 1 JANUARY–31 DECEMBER 2018 PERIOD

Other operating income

Other operating income for the period amounted to KSEK 3,766 (0) and refers to the Horizon 2020 grant.

Operating profit/loss

Operating loss for the period amounted to KSEK -27,861 (-21,299), a change of KSEK -6,562 compared with the first quarter of the preceding year. In 2017, resources for development were increased. Additional investments in 2018 continued to raise the cost level.

Profit/loss for the period

Loss for the period amounted to KSEK -27,634 (-21,322). Loss per share before dilution amounted to SEK -1.27 (-1.32) and loss per share after dilution to SEK -1.27 (-1.32).

Liquidity and cash flow

- Cash flow from operating activities was KSEK -10,394 (-19,906). The improved year-on-year figure was mainly attributable to deferred income from Horizon 2020.
- Cash flow from investing activities was KSEK -3,714 (-4,266). During the period, investments were made in laboratory equipment and patents.
- Cash flow from financing activities was KSEK +38,769 (+42,613).
- Cash flow for the quarter was KSEK +24,661 (+18,441).
- At the end of the period, the Group's cash and cash equivalents amounted to KSEK 61,606 (36,943).

The existing cash and cash equivalents will last at the current activity level until the third quarter of 2020.

Financial position

At 31 December 2018, the equity/assets ratio was 71% (90) and equity amounted to KSEK 51,023 (39,888). On the same date, total assets amounted to KSEK 71,644 (44,152).

In May 2017, Idogen was granted research funding of MEUR 2.9 (just over MSEK 29) by Horizon 2020 (the EU Framework Programme for Research and Innovation) to develop the company's tolerogenic cell therapy for the treatment of anti-factor VIII neutralising antibodies in patients with severe haemophilia A. The full amount of funding will be paid out over the course of the project. In January, MEUR 1.2 had been received and in December MEUR 0.3 was paid out. The remaining funds are expected to be paid out over the next 24 months. The amount received has been recognised as deferred income. Ongoing settlement is taking place at the same rate as costs are entered for the project.

INVESTMENTS

Idogen's investments have previously comprised costs for patents only. During the period, the company's facilities were adapted for the laboratory. Various machinery was also purchased. During the period, the laboratory was relocated to the new facilities. The investments amounted to MSEK 3.7 (4.2).

NEW SHARE ISSUE

The Board of Idogen convened an Extraordinary General Meeting on 5 November in Lund. The Meeting approved a rights issue to raise capital of MSEK 60.6. The rights issue was 80% underwritten by a syndicate including new strategic investors. The subscription price was SEK 1.75 per new share. The rights issue was subscribed to 80%.
Idogen raised MSEK 38.7 in capital from the rights issue after issue costs.
The rights issue resulted in cash and cash equivalents to run operations until the third quarter of 2020.

EVENTS AFTER THE BALANCE-SHEET DATE

No other significant events affecting the interim financial statements occurred after the end of the period.

EMPLOYEES AND ORGANISATION

At 31 December 2018, the number of employees was 11.

Idogen's organisation comprises all of the competencies and experience required to run the company. Close collaboration has been established with a number of key consultants in patents, preclinical management, clinical trials, cell therapy, pharmaceutical development, manufacturing, documentation, quality assurance, finance and legal matters.

GENERAL MEETING AND ANNUAL REPORT

The Annual General Meeting will be held on 25 June 2019 at 3:00 p.m. in Gamla Gästmatsalen, Medicon Village, Scheelevägen 2, Lund, Sweden. Shareholders will be notified by announcement in *Post- och Inrikes Tidningar* (the Swedish Official Gazette) and on the company's website, as well as by announcement in *Svenska Dagbladet* that notice has been given, no earlier than six weeks and no later than four weeks before the Meeting.

Shareholders who wish to have a matter addressed by the AGM should send a written request to Idogen AB, Att: Board of Directors, Medicon Village, Scheelevägen 2, SE-223 81 Lund, Sweden. Such requests must be received by the Board of Directors no later than seven weeks prior to the AGM, or within sufficient time for the matter to be included, if requested, in the notice of the AGM.
Idogen's 2018 Annual Report is expected to be available for download on the company's website during the last week of May 2019.

NOMINATION COMMITTEE

In accordance with the AGM's decision, the three largest shareholders at the end of the third quarter of 2018 were asked to nominate their representatives for the Nomination Committee. The following representatives – Rolf Ehrnström (as Chairman of the Committee) for Ventac Holdings (Cyprus) Ltd, Leif G Salford and Hans-Olov Sjögren – were appointed to the Nomination Committee. The Nomination Committee's proposals will be presented in early-April.

RISKS AND UNCERTAINTIES

In addition to general uncertainty related to research and development activities and delays in clinical trials, there are no known trends, uncertainties, potential claims or any other demands, commitments or events that are reasonably likely to have a material adverse effect on the company's prospects.
A detailed presentation of various risks can be found in the Annual Report (pages 28–29) and in the prospectus for the rights issue (pages 15–18).

EQUITY

Equity was mainly impacted by the issues in 2017 and 2018, and by earnings during the periods. At 31 December 2018, equity amounted to MSEK 51.0 (39.9).

THE SHARE AND SUBSCRIPTION WARRANTS

The share

Loss after tax divided by the average number of shares for the period amounted to SEK -1.27 (-1.32) for the reporting period. At the end of December 2018, Idogen had approximately 2,300 shareholders. The number of shares was 48,491,533 (20,778,472). In addition to the shares, there are 8,555,883 TO3 subscription warrants.

Name	No. of shares	Percentage of votes/capital (%)
SEB Life	5,795,349	12.0
Danica Pension	5,714,283	11.8
HCN	2,197,904	4.5
Jens Miöen	2,014,497	4.2
Others	32,769,498	67.6
Total	**48,491,533**	**100.0**

TO2 redemption
The period for converting TO2 warrants into ordinary shares in Idogen AB ended on 18 May 2018. A total of 3,318 TO2 warrants were exercised to purchase a total of 3,318 shares – an exercise rate of about 0.04%. The subscription generated net proceeds of KSEK 20 for Idogen, before issue costs. The subscription price of SEK 6 per share exceeded the market price, which was SEK 3.25 at the beginning of the period.

Summary of terms for the TO3 subscription warrants
Each subscription warrant entitles the holder to subscribe for one new share at a subscription price equal to 70% of the volume-weighted average price of the company's shares during the period of 25 February–15 March 2019. However, the subscription price must not be less than SEK 6 per share or more than SEK 13 per share. The subscription price is unchanged after the rights issue in 2018. The warrants can be used to subscribe for shares during the period of 19 March–1 April 2019.

PROPOSED ALLOCATION OF PROFIT
The Board of Directors and Chief Executive Officer propose that no dividend (SEK 0.0/share, the same as in the preceding year) be paid for the 1 January 2018–31 December 2018 financial year.

ACCOUNTING POLICIES
This interim report has been prepared in accordance with RFR 2, Accounting for Legal Entities. The report has been prepared in accordance with IAS 34, with consideration for the exceptions and additions to IFRS specified in RFR 2. The company has no subsidiary and no consolidated financial statements are therefore given. This means IFRS-compliant financial statements are not applicable.

The accounting policies are presented in the Annual Report on pages 35–37. No changes have been made to these policies.

Idogen has received a grant from the EU (Horizon 2020) planned to be paid in 2018-2020. The company shall deliver five different projects within the framework of the grant. Obtained portions of the grant be booked as deferred income when they are paid. The grant is reported systematically as other revenue, for the same periods as the costs the grant is intended to compensate for.

AUDITOR'S REPORT
This year-end report has not been audited.

ASSURANCE BY THE BOARD OF DIRECTORS

The Board of Directors and Chief Executive Officer certify that this interim report presents a true and fair view of the company's operations, financial position and results and describes the significant risks and uncertainties faced by the company.

Lund, February 6, 2019

The Board of Directors of Idogen AB

Agneta Edberg, Chairman

Christina Herder

Karin Hoogendoorn

Leif G. Salford

Lars Hedbys, Chief Executive Officer

CONDENSED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

(Amounts in KSEK)	2018 3 months Oct-Dec	2017 3 months Oct-Dec	2018 12 months Jan-Dec	2017 12 months Jan-Dec
Net sales	-	-	-	-
Other operating income	3,766	0	3,766	0
Total income	**3,766**	**0**	**3,766**	**0**
Operating expenses				
Other external costs	-5,207	-5,321	-21,489	-16,452
Employee benefit expenses	-3,057	-1,893	-9,147	-4,772
Depreciation of tangible assets	-298	-75	-991	-75
Operating loss	**-4,796**	**-7,289**	**-27,861**	**-21,299**
Interest income and similar profit items	-15	0	529	0
Interest expense and similar loss items	5	-26	-302	-23
Loss before tax	**-4,806**	**-7,315**	**-27,634**	**-21,322**
Tax	**-**	**-**	**-**	**-**
LOSS FOR THE PERIOD	**-4,806**	**-7,315**	**-27,634**	**-21,322**
OTHER COMPREHENSIVE INCOME	-	-	-	-
COMPREHENSIVE INCOME FOR THE PERIOD	**-4,806**	**-7,315**	**-27,634**	**-21,322**

CONDENSED STATEMENT OF FINANCIAL POSITION

(Amounts in KSEK)	Dec 31 2018	Dec 31 2017
ASSETS		
Intangible assets		
Patents	4,060	3,230
Total intangible assets	**4,060**	**3,230**
Tangible assets		
Leasehold improvements	1,766	663
Equipment, tools, fixtures and fittings	2,890	2,100
Total tangible assets	**4,656**	**2,764**
Total assets	**8,716**	**5,994**
Other receivables	676	752
Prepaid expenses and accrued income	647	498
Cash and bank balances	61,605	36,943
Total current assets	**62,927**	**38,193**
TOTAL ASSETS	**71,644**	**44,187**
EQUITY		
Restricted equity		
Share capital	3,394	1,454
Fund for development expenses	2,918	2,087
Total restricted equity	**6,312**	**3,542**
Non-restricted equity		
Share premium reserve	97,701	60,872
Profit brought forward	-25,357	-3,204
Loss for the year	-27,634	-21,322
Total non-restricted equity	**44,710**	**36,347**
Total equity	**51,023**	**39,887**
Current liabilities		
Accounts payable – trade	7,175	3,343
Other liabilities	1,146	250
Accrued expenses and deferred income	12,300	706
Total current liabilities	**20,621**	**4,298**
TOTAL EQUITY AND LIABILITIES	**71,644**	**44,187**

CONDENSED STATEMENT OF CHANGES IN EQUITY

(Amounts in KSEK)	Share capital	Fund for development expenses	Share premium reserve	Profit brought forward	Profit/ loss for the year	Total equity
Opening balance at 1 Jan 2017	**855**	**661**	**18,858**	**10,822**	**-12,599**	**18,597**
Appropriation of profits as per AGM	-	-	-	-12,599	12,599	-
New issue	599	-	50,736	-	-	51,335
Capital raising expenses	-	-	-8,721	-	-	-8,721
Allocation to fund for development expenses	-	1,427	-	-1,427	-	0
Loss for the period	-	-	-	-	-21,322	-14,007
Closing balance at 30 December 2017	**1,455**	**2,087**	**60,872**	**-3,204**	**-21,322**	**39,888**

(Amounts in KSEK)	Share capital	Fund for development expenses	Share premium reserve	Other non-restricted equity	Profit/ loss for the year	Total equity
Opening balance at 1 Jan 2018	**1,454**	**2,087**	**60,872**	**- 3,204**	**-21,322**	**39,888**
Appropriation of profits as per AGM	-	-	-	-21,322	21,322	-
New issue	1,940	-	46,572	-	-	48,512
Capital raising expenses	-	-	-9,743	-	-	-9,743
Allocation to fund for development expenses		831		-831		
Loss for the period	-	-	-	-	-27,634	-27,634
Closing balance at 31 December 2018	**3,394**	**2,087**	**97,701**	**-24,526**	**-27,634**	**51,023**

Shareholdings disclosure	**No. of shares**
Holding/value at beginning of the year	20,778,472
Holding/value at 31 Dec 2018	48,491,533
Subscription warrants issued, TO3	8,555,883
Total no. of shares after fully subscribed issue	**57,047,416**

CONDENSED STATEMENT OF CASH FLOWS

(Amounts in KSEK)	2018 3 months Oct-Dec	2017 3 months Oct-Dec	2018 12 months Jan-Dec	2017 12 months Jan-Dec
OPERATING ACTIVITIES				
Operating loss before financial items	-4,796	-7,289	-27,861	-21,299
Reversal of depreciation/amortisation	296	75	991	75
Interest received	-15	0	529	0
Interest paid	5	-26	-302	-23
Cash flow from operating activities before changes in working capital	**-4,508**	**-7,240**	**-26,643**	**-21,247**
Increase/Decrease in prepaid expenses and accrued income	83	-303	-108	-887
Increase/Decrease in accounts payable	4,459	-678	3,832	2,347
Increase/Decrease in other current liabilities	-467	-30	12,525	-120
Cash flow from operating activities	**-432**	**-8,250**	**-10,394**	**-19,906**
Investing activities				
Investment in intangible assets	-216	-466	-831	-1,427
Investment in tangible assets	-250	-2,237	-2,883	-2,839
Cash flow from investing activities	**-466**	**-2,703**	**-3,714**	**-4,266**
Financing activities				
New issue	38,749	0	38,769	42,614
Cash flow from financing activities	**38,749**	**0**	**38,769**	**42,614**
Cash flow for the period	37,851	-10,953	24,661	18,441
Cash and cash equivalents at the beginning of the period	23,754	47,896	36,943	18,502
Cash and cash equivalents at the end of the period	**61,605**	**36,943**	**61,605**	**36,943**

FINANCIAL CALENDAR

Interim report January – March 2019	May 28 2019
Interim report January – June 2019	August 20 2019
Interim report January – September 2019	October 22 2019
Year-end report 2019	February 11 2020

IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT:

Lars Hedbys, Chief Executive Officer
Tel: +46 (0)46-275 63 30,
E-mail: lars.hedbys@idogen.com

ADDRESS

Idogen AB
Medicon Village, Scheelevägen 2, SE-223 81 Lund, Sweden

This is an English version of the original Swedish report communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This information is such that Idogen AB is obligated to publish under the EU Market Abuse Regulation (MAR) and the Swedish Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, on February 6, 2019.